Elsevier

Obstetrics & Gynecology

Volume 89, Issue 2, February 1997, Pages 272-275
Obstetrics & Gynecology

Female alloimmunization with antibodies known to cause hemolytic disease

https://doi.org/10.1016/S0029-7844(96)00434-6Get rights and content

Objective

To determine the current frequency of red blood cell antigen alloimmunizations that are capable of causing hemolytic disease and would be suitable for prenatal DNA studies.

Methods

We reviewed blood-bank records at a single large tertiary center to identify patients with a positive antibody screen between January 1993 and June 1995. Data were analyzed based on age, gender, and specific blood-group alloimmunizations. The incidence of antibodies as published in the literature was reviewed and compared with our data.

Results

We identified 452 women who had a positive antibody screen. The frequencies of specific alloimmunization relevant to the development of fetal hemolytic disease were: anti-D, 18.4%; anti-E, 14%; anti-c, 5.8%; anti-C, 4.7%; Kell group, 22%; anti-MNS, 4.7%; anti-Fya (Duffy), 5.4%; and anti-Jka, 1.5%. Compared with other populations, in our group the frequency of antibodies to RhD decreased and Kell alloimmunization increased between 1967 and 1996.

Conclusions

Despite the use of rhesus immune globulin, anti-D is still a common antibody identified in women presenting to a tertiary care center. The frequency of the Kell-group alloimmunization is higher among the central New York female population than in other populations. Rhesus and Kell antigen status can be determined by DNA studies. Research in prenatal determination of fetal antigen status should continue, as alloimmunization to these antigens is common.

References (18)

There are more references available in the full text version of this article.

Cited by (112)

  • Neonatal Erythrocyte Disorders

    2023, Avery's Diseases of the Newborn
  • Relationship between blood type and outcomes following COVID-19 infection

    2021, Seminars in Vascular Surgery
    Citation Excerpt :

    Like ABO types, Rh-type refers to proteins on surface of red blood cells [47]. Clinically, this system plays an important role in blood transfusion and erythroblastosis fetalis [47,48]. Recent studies also demonstrate a significant impact in COVID-19 infection and illness as well.

  • Alloimmunization in Pregnancy

    2020, Immunologic Concepts in Transfusion Medicine
  • Red Blood Cell Alloimmunization in the Pregnant Patient

    2018, Transfusion Medicine Reviews
    Citation Excerpt :

    Reported rates of alloimmunization in women of childbearing potential vary greatly depending upon the period and manner in which the data were collected. In the United States, a representative series of 22 102 blood samples from women of reproductive potential (age 15–44 years) identified RBC antibodies in 1.15%, of whom 18% had multiple antibodies [18]. Luckily, rates of clinically significant HDFN are much lower at 3/100000 to 80/100000 live births [19].

View all citing articles on Scopus
View full text